SCHEMBL195131

SCHEMBL195131

Cc1cc(CCl)c(Cl)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD44 P16070 1/20 0.42
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
CYP3A4 P08684 1/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PON1 P27169 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32
SIRT1 Q96EB6 1/20 0.31
AKR1B1 P15121 1/20 0.30
ALOX15 P16050 2/20 0.30
ALOX12 P18054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11431032 0.80 CD44 (0.42) CD44GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL12811480 0.80 GRIN2D (0.47) CD44GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11779597 0.78 AHR (0.40) CYP3A4KMT2AMAPK1ALOX15ALOX12
SCHEMBL13696818 0.78 IDO1 (0.46) CD44GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17466157 0.78 CD44 (0.41) CD44GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17466153 0.78 CD44 (0.41) CD44GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7597819 0.78 IDO1 (0.36) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4056315 0.76 TAAR1 (0.43) KMT2AKDM4EALDH1A1HSD17B10
SCHEMBL10490655 0.76 PON1 (0.31) KMT2APON1KDM4EMAPK1RAB9A
SCHEMBL442987 0.75 ALDH1A1 (0.42) KMT2ANPSR1PON1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754100-B2 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-17 US disclosed
EP-2615090-A1 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors Eisai R&D Management Co., Ltd. (JP) 2013-07-17 EP disclosed
EP-2401276-B1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MAN CO LTD (JP) 2013-06-05 EP disclosed
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors EISAI R&D MANAGEMENT CO., LTD., (JP) 2012-03-01 US disclosed
EP-2401276-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS Eisai R&D Management Co., Ltd. (JP) 2012-01-04 EP disclosed
WO-2010098487-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors BACE1, APP, PSEN1 CD44 4644/4885GRIN2D 1391/4885GRIN3B 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.